From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: INS

Search articles by EPIC code

Instem – interims, emphasises revenue increase and adjusted profit… but what about cash?

Earlier this month I concluded on company which describes itself as “a leading provider of IT solutions to the global life sciences market” Instem plc (INS) that, with the shares up to 660p, greater and more consistent delivery is required – in overall financial terms, not just contract announcements. Now half-year results...and the shares currently down to below 600p.


Instem – argues new project “highlights the strength of our product suite”, what about the recent profit warning?

Life sciences market IT provider Instem (INS) has announced grant funding for involvement in a research project, emphasising it “highlights the strength of our product suite, which supports the continued global demand for reliable alternatives to traditional testing methods - with industry and regulators alike increasingly recognizing the huge benefits of computational toxicology approaches”...


Instem – profit warning, how much recovery ahead?

Life sciences market IT provider Instem (INS) has announced 2021 results emphasising “the combination of increasing demand for regulatory-backed solutions and a growing demand for artificial intelligence and in silico solutions in the drug R&D process underpins our confidence in further leveraging our software and service portfolio”. So what of a current share price response to below 700p, down more than 12%?!


Instem – “as a result of strong institutional investor demand”, ‘long term shareholders’ including directors sell… at a good price then?

Provider of IT services to the life sciences market, Instem (INS) has announced shareholders including the DG 2008 Discretionary Settlement (of which Chairman David Gare and his wife are trustees) and non-executive director David Sherwin have sold shares… “as a result of strong institutional investor demand following our recent results”. With such demand seemingly unable to be met by the market, a good price in relation to a last close 330p share price then?...

Page 1 of 2 (12 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments